GeneDx Holdings Corp. announced that CEO Katherine Stueland will step down on or before December 15, 2026, to be succeeded by industry veteran Everett Cunningham. Stueland will remain in an advisory role through January 31, 2027, to ensure a smooth transition. The company reaffirmed its full year 2026 financial guidance as originally provided on November 9, 2026.
The filing confirms CEO Katherine Stueland will step down on or before December 15, 2026, succeeded by Everett Cunningham, a commercial veteran from Quanterix, Illumina, Exact Sciences and Quest Diagnostics. A CEO change creates execution and personnel-retention uncertainty, but it is presented as a planned handover with a transition advisory period through January 31, 2027, and the company reaffirmed its full year 2026 guidance issued November 9, 2026, which limits downside surprises.
- • CEO transition effective on or before December 15, 2026
- • Full year 2026 financial guidance reaffirmed (as of November 9, 2026)
- • Departure of the CEO who led the company's transformation over five and a half years
- • Risk of disruption to employees, customers, payors and partners during the transition (cited in the filing)